Click here for Annual Conference details
Interstitial Lung Diseases Interdisciplinary Network

NICE Publish Nintedanib Guidance

The long awaited guidance on the use of Nintedanib to treat IPF has been published by NICE.

Nintedanib for treating idiopathic pulmonary fibrosis

NICE technology appraisal guidance [TA379] Published date: January 2016

Recommendations

1. Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:

• the person has a forced vital capacity (FVC) between 50% and 80% of predicted
• the company provides nintedanib with the discount agreed in the patient access scheme
• treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12 month period.
2. People whose treatment with nintedanib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

To download the full guidance go to http://www.nice.org.uk/guidance/ta379

The National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication. While NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.
This is good news for patients with IPF who should soon have more than one treatment option available to them.

related posts

Get in Touch With Us